Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth ibuprofen comments

This article was originally published in The Tan Sheet

Executive Summary

Advil marketer requests 90-day extension to submit comments on ibuprofen inclusion in internal analgesics tentative final monograph. In Oct. 11 letter to FDA, Wyeth notes it delayed completion of its comments "so that consideration could be given to the impact of the NDAC discussions on product labeling." Firm says it will use the extra time to review safety data FDA cited in support of new GI, renal label warning statements if ibuprofen is added to TFM. Wyeth also might conduct consumer research "that could provide information relevant to the crafting of a label which achieves the intended communication goal and further maximizes safe and appropriate use," the letter states. FDA issued the proposed amendment in August (1"The Tan Sheet" Aug. 26, 2002, p. 3)...

You may also be interested in...



FDA internal analgesics

Comment period on agency's proposal to amend internal analgesics tentative final monograph to include ibuprofen reopened until Sept. 2, FDA says in 1June 4 Federal Register notice. In October, Wyeth requested additional time to evaluate labeling suggestions made during NDAC meeting on internal analgesic products (2"The Tan Sheet" Oct. 28, 2002, In Brief). Firm also said it might conduct consumer research on information relevant to crafting appropriate label. FDA "acknowledges that additional time may be beneficial to fully evaluate and respond to the issues." Agency proposed the amendment in August (3"The Tan Sheet" Aug. 26, 2002, p. 3)...

Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion

Clinical study data and adverse event reports support inclusion of a warning on OTC ibuprofen labeling to alert consumers at risk for developing acute renal failure to consult a doctor, FDA says

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

UsernamePublicRestriction

Register

PS094712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel